SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - APLT

Core Viewpoint - A class action lawsuit has been filed against Applied Therapeutics, alleging securities fraud and unlawful business practices related to the company's clinical trial issues and FDA communications [1][4]. Group 1: Class Action Details - The class action lawsuit is initiated by Pomerantz LLP, targeting Applied Therapeutics and its officers/directors [4]. - Shareholders who purchased or acquired DMC securities during the Class Period can request to be appointed as Lead Plaintiff by February 18, 2025 [5]. Group 2: FDA Communications - On December 2, 2024, Applied Therapeutics received a "warning letter" from the FDA, highlighting issues with electronic data capture and a dosing error during a clinical trial [2]. - The company plans to respond to the FDA's concerns within the allowed 15 business days [2]. Group 3: Stock Price Impact - Following the announcement of the FDA's Complete Response Letter (CRL) on November 27, 2024, Applied Therapeutics' stock price dropped by $1.64, or 16.06%, closing at $8.57 per share [6]. - Over the next three trading sessions, the stock price further declined by $0.46, or 26.29%, closing at $1.29 per share on December 5, 2024 [9]. Group 4: Company Background - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered billions in damages for class members over its 85-year history [7].